Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
Nanomedicine (Lond)
; 11(3): 235-47, 2016 Feb.
Article
em En
| MEDLINE
| ID: mdl-26787319
ABSTRACT
BACKGROUND:
This study explores the use of hydrophilic poly(ethylene glycol)-conjugated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NPs) as delivery system to improve the antitumor effect of antiobesity drug orlistat for triple-negative breast cancer (TNBC) therapy by improving its bioavailability. MATERIALS &METHODS:
PLGA-PEG-NPs were synthesized by emulsion-diffusion-evaporation method, and the experiments were conducted in vitro in MDA-MB-231 and SKBr3 TNBC and normal breast fibroblast cells.RESULTS:
Delivery of orlistat via PLGA-PEG-NPs reduced its IC50 compared with free orlistat. Combined treatment of orlistat-loaded NPs and doxorubicin or antisense-miR-21-loaded NPs significantly enhanced apoptotic effect compared with independent doxorubicin, anti-miR-21-loaded NPs, orlistat-loaded NPs or free orlistat treatments.CONCLUSION:
We demonstrate that orlistat in combination with antisense-miR-21 or current chemotherapy holds great promise as a novel and versatile treatment agent for TNBC.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polietilenoglicóis
/
Ácido Poliglicólico
/
RNA Mensageiro
/
RNA Antissenso
/
Ácido Láctico
/
Neoplasias de Mama Triplo Negativas
/
Lactonas
Limite:
Female
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2016
Tipo de documento:
Article